Samsung Biologics Plans $2.2 Billion Fundraising for PolyPeptide Acquisition
Samsung Biologics intends to raise approximately 3 trillion won through a rights offering to finance its proposed acquisition of peptide maker PolyPeptide Group. The capital injection will support the company’s broader expansion strategy in the contract development and manufacturing sector.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (46/100)Sources
Samsung Biologics to Raise $2.2 Billion to Fund PolyPeptide Deal
Samsung Biologics Co. is seeking to raise about 3 trillion won ($2.2 billion) in a rights offering to fund its acquisition of PolyPeptide Group.
By Youkyung Lee and Denny Thomas
Read full article →Samsung Biologics to raise W3tr in rights issue for peptide maker deal
Samsung Biologics is planning to raise over 3 trillion won ($2.2 billion) through a share offering to fund its acquisition of a peptide manufacturer and a new production campus, as competition among global drugmakers intensifies. In a regulatory filing Friday, Samsung Biologics said its board approved the offering, issuing 2.27 million new shares at 1,322,000 won apiece, a 15 percent discount that will expand its share count by 4.9 percent. Of the proceeds, 2.71 trillion won will fund the acquis
By The Korea Herald
Read full article →Samsung Biologics to raise 3 tln won via rights offering
SEOUL, Aug. 28 (Yonhap) -- Samsung Biologics announced Friday it would raise 3 t...
By Kang Jae-eun
Read full article →Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion - Taiwan News
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion Taiwan News
Read full article →
